LA JOLLA, CA – May 12, 2025 – In a landmark study that could redefine the treatment landscape for a myriad of debilitating conditions, scientists at the Salk Institute have identified a group of proteins, known as estrogen-related receptors (ERRs), as crucial regulators of energy metabolism and muscle function. Their findings suggest that targeting these receptors could unlock a powerful new therapeutic strategy to repair dysfunctional mitochondria, the cellular powerhouses responsible for generating energy, and alleviate muscle fatigue in millions worldwide.
Published today in the prestigious Proceedings of the National Academy of Sciences, the research highlights ERRs’ indispensable role in boosting mitochondrial growth and energetic output, particularly within muscle cells. This discovery opens promising avenues for developing drugs to combat metabolic disorders such as muscular dystrophy, as well as age-related muscle weakness and the systemic energy deficits associated with diseases like cancer, multiple sclerosis (MS), heart disease, and dementia.
The breakthrough builds upon decades of foundational work at the Salk Institute, underscoring the potential for a new class of treatments aimed at restoring cellular energy supplies, thereby enhancing not only muscle strength but also potentially improving the function of vital organs like the brain and heart.
Unlocking Cellular Powerhouses: The Breakthrough Discovery
At the very core of our existence, within nearly every cell of our body, lie tiny, bean-shaped organelles called mitochondria. These "cellular energy factories" are responsible for turning the food we eat into adenosine triphosphate (ATP), the usable energy currency that powers every biological process, from the beating of our hearts to the firing of our neurons and, critically, the contraction of our muscles.
However, this intricate system is far from infallible. Mitochondrial dysfunction is a pervasive and challenging health issue. Approximately 1 in 5,000 individuals are born with genetic defects that impair mitochondrial function, leading to severe metabolic disorders. Beyond these congenital conditions, millions more develop metabolic dysfunction later in life, often as a consequence of aging or in association with a spectrum of chronic diseases. The list is extensive and growing, encompassing neurodegenerative conditions like Alzheimer’s and Parkinson’s disease, autoimmune disorders such as multiple sclerosis, cardiovascular diseases, various forms of cancer, and even the pervasive fatigue experienced by many in the general population.
The consequences of compromised mitochondrial function are profound: a persistent energy deficit at the cellular level translates into systemic problems, most notably muscle weakness, debilitating fatigue, and impaired organ function. Despite the widespread impact of these conditions, effective treatments for mitochondrial dysfunction have remained elusive, leaving patients with limited options for managing their symptoms and improving their quality of life.
It is against this backdrop that the Salk Institute’s latest findings emerge as a beacon of hope. The research team, led by senior author Ronald Evans, a professor and the March of Dimes Chair in Molecular and Developmental Biology at Salk, has identified estrogen-related receptors as a novel and highly effective therapeutic target. Their meticulous investigation revealed that ERRs play a pivotal role in regulating muscle cell metabolism, particularly in response to increased energy demands, such as those encountered during physical exercise. When muscles require more fuel, these receptors act as critical orchestrators, not only increasing the sheer number of mitochondria within muscle cells but also significantly enhancing their energetic output, thereby ensuring a robust and sustained energy supply. This dual action positions ERRs as a uniquely potent target for intervention.
A Deeper Dive into Estrogen-Related Receptors (ERRs)
The Unsung Heroes of Metabolism
Estrogen-related receptors belong to a super-family of proteins known as nuclear hormone receptors. This family, whose groundbreaking discovery was spearheaded by Professor Evans in the 1980s, comprises hormone-activated receptors that bind directly to our DNA. By doing so, they act as molecular switches, controlling which genes are turned "on" or "off," thereby regulating a vast array of physiological processes. While classic estrogen receptors are well-known for their roles in reproductive health and bone density, ERRs, despite their structural similarity, have historically been much less understood in terms of their specific functions.
Professor Evans’ lab first discovered estrogen-related receptors in 1988, and his team was among the first to recognize their potential involvement in energy metabolism. Intriguingly, ERRs are found in particularly high concentrations in parts of the body that demand substantial energy to function optimally, such as the heart and the brain – organs renowned for their relentless metabolic activity. This distribution pattern naturally led Evans’ team to hypothesize that ERRs might play a similarly critical role in regulating metabolism within another high-energy organ system: skeletal muscle. Given muscle’s incredible adaptability and its constant need for fuel, especially during physical exertion, it represented a compelling area for further investigation into ERR function.
The Critical Role in Muscle Function and Exercise
Skeletal muscles are prodigious consumers of energy. Whether performing routine daily tasks or engaging in strenuous exercise, they require a constant and ample supply of ATP. It is a well-established physiological principle that physical activity is one of the most potent stimuli for muscle adaptation, triggering a process known as mitochondrial biogenesis. During biogenesis, muscle cells increase the number and size of their mitochondria, essentially expanding their energy-producing capacity to meet heightened demands. This adaptive response is fundamental to improving endurance, strength, and overall physical performance.
However, for individuals grappling with muscular and metabolic disorders, or those weakened by aging or chronic illness, engaging in sufficient exercise to stimulate mitochondrial biogenesis is often an insurmountable challenge. The very act of physical exertion, which healthy individuals use to bolster their cellular energy factories, becomes a barrier for those most in need of metabolic improvement. This therapeutic dilemma has spurred scientists worldwide to search for alternative, pharmacological ways to stimulate this vital process, seeking to confer the benefits of exercise without the physical strain.
"Mitochondria are our cells’ energy factories, so the more we exercise, the more mitochondria our muscles need," explains Weiwei Fan, the study’s first author and a staff scientist in Evans’ lab. "This got us thinking — if we could understand how exercise induces mitochondrial biogenesis, we might be able to target those same mechanisms pharmacologically to trigger this process in people who are too weak to exercise." This fundamental question laid the groundwork for their groundbreaking investigation, aiming to bridge the gap between biological insight and clinical application.
Chronology of Discovery: From Hypothesis to Validation
The Salk team embarked on a systematic investigation to precisely define the role of estrogen-related receptors in muscle cell metabolism and, crucially, in the exercise-induced adaptation of muscle. Their journey from hypothesis to validation was meticulously structured, leveraging advanced genetic techniques to dissect the intricate functions of these receptors.
Methodology: Unraveling ERR Function in Mice
To determine whether estrogen-related receptors played a role in muscle cell metabolism, Fan and his colleagues employed a sophisticated genetic approach. They utilized mouse models, a standard and invaluable tool in biomedical research due to their genetic similarity to humans and the ability to precisely manipulate specific genes. The researchers specifically deleted three different forms, or isoforms, of the estrogen-related receptors—alpha (ERRα), beta (ERRβ), and gamma (ERRγ)—within the muscle tissues of these mice. This targeted deletion allowed them to observe the direct consequences of ERR absence on muscle mitochondrial activity and overall metabolic function, isolating the impact of each receptor type.
Their initial observations revealed a complex interplay between the different ERR isoforms. They found that ERRα was by far the most abundant type of receptor in muscle tissue. However, surprisingly, the loss of this single, most prevalent receptor had only mild impacts on muscle tissue under normal, sedentary conditions. This suggested a degree of redundancy or compensatory mechanisms at play. Further investigation illuminated that the gamma receptor (ERRγ), despite making up only a small fraction—approximately 4%—of the total estrogen-related receptors, was remarkably capable of compensating for the absence of ERRα under these baseline conditions. This compensatory ability highlighted the robustness of the metabolic system and the intricate regulatory networks that ensure energy homeostasis.
The true impact of ERR deficiency became starkly evident when the researchers deleted both the alpha and gamma types of receptors simultaneously. This dual deletion led to severe impairments in muscle mitochondrial activity, profoundly affecting their shape, size, and overall functional capacity. Mitochondria in these mice were not only fewer in number but also appeared malformed and less efficient, signaling a critical, non-redundant role for the combined action of ERRα and ERRγ in maintaining robust mitochondrial health and function.
The Exercise Connection: Pinpointing ERRα’s Indispensable Role
The question then arose: if ERRα’s absence alone had only mild effects under normal conditions, why was there such an apparent "excess" of this alpha-type receptor in muscle? The team hypothesized that ERRα’s true significance might emerge under conditions of increased metabolic demand, specifically during exercise, where muscles are pushed to adapt and grow.
To test this hypothesis, the researchers subjected their genetically modified mice to an exercise regimen, allowing them to run on mechanical wheels. This controlled exercise protocol was designed to trigger mitochondrial biogenesis, the natural process by which muscle cells increase their mitochondrial count to meet heightened energy requirements. This experiment proved to be pivotal. It unequivocally revealed that losing ERRα alone could entirely block exercise-induced mitochondrial biogenesis. Despite the compensatory capabilities of ERRγ under sedentary conditions, ERRα emerged as the indispensable driver when muscles needed to adapt to physical stress. Without ERRα, the muscles simply could not ramp up their energy factory production in response to exercise, leading to profound energetic deficits and impaired performance.
Previous studies in the field had established that exercise-induced mitochondrial growth was largely driven by another protein known as PGC1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha). PGC1α is often referred to as the "master regulator" of mitochondria throughout the body, orchestrating many aspects of their function and biogenesis. However, PGC1α presents a significant challenge for therapeutic drug development: unlike nuclear hormone receptors such as ERRs, PGC1α cannot bind directly to genes to turn them "on" or "off." Instead, it relies on partner proteins to execute its regulatory functions, acting indirectly. This indirect mechanism makes PGC1α a more complex and therefore more difficult target for the development of specific, small-molecule drugs.
This distinction proved critical for the Salk team. When Evans’ lab meticulously examined the muscle cells after exercise, they discovered a crucial partnership: PGC1α was indeed present and active, but it was working in concert with ERRα to drive mitochondrial biogenesis. The key insight, however, was that unlike its co-regulator PGC1α, ERRα possesses the inherent ability to bind directly to mitochondrial energetic genes. This direct binding capability allows ERRα to switch these genes "on," thereby initiating and enhancing the production of new mitochondria and boosting their energy output. This direct action makes ERRα a significantly more promising and accessible target for therapeutic drug development, offering a direct "on-switch" for improving muscle’s mitochondrial performance.
Supporting Data and Scientific Rigor
The integrity and robustness of these findings are underpinned by a rigorous scientific process and a collaborative research effort. The study, titled "[Insert Actual Title if Available, otherwise generalize]," was officially published in the Proceedings of the National Academy of Sciences on May 12, 2025. This peer-reviewed publication ensures that the methodology, results, and conclusions have been scrutinized and validated by leading experts in the field.
The research involved a comprehensive team of scientists from various institutions, highlighting the collaborative nature of modern biomedical discovery. In addition to the core Salk Institute team, including authors Hui Wang, Lillian Crossley, Mingxiao He, Hunter Robbins, Chandra Koopari, Yang Dai, Morgan Truitt, Ruth Yu, Annette Atkins, and Michael Downes, the study also benefited from expertise contributed by Tae Gyu Oh of Salk and the University of Oklahoma, and Christopher Liddle of the University of Sydney, Australia. Such multi-institutional collaboration often brings diverse perspectives and specialized technical skills, strengthening the overall quality and reach of the research.
The extensive scope of the work was made possible through significant financial backing from a consortium of highly respected funding bodies. These include the National Institutes of Health (NIH), a primary source of funding for biomedical research in the United States, through multiple grants (P01HL147835, DK057978, DK120515, 1R21OD030076, CCSG P30CA23100, CCSG P30 CA014195, CCSG P30 CA014195, P30 AG068635). Additional support was provided by the Department of the Navy (N00014-16-1-3159), the Larry L. Hillblom Foundation, Inc. (2021-D-001-NET), the Wu Tsai Human Performance Alliance, the Henry L. Guenther Foundation, and the Waitt Foundation. This broad base of financial support underscores the perceived importance and potential impact of the research within the scientific and philanthropic communities. The use of controlled genetic deletion models in mice, coupled with precise physiological measurements during exercise, further reinforces the scientific rigor of the study, providing strong evidence for the causative role of ERRs in mitochondrial biogenesis and function.
Official Responses and Expert Commentary
Insights from the Lead Researchers
The Salk Institute team is cautiously optimistic about the far-reaching implications of their discovery. Senior author Ronald Evans, a towering figure in the field of nuclear hormone receptors, articulated the profound significance of their findings. "Estrogen-related receptors look a lot like classic estrogen receptors, but their function has been much less understood," says Evans. "Our lab discovered estrogen-related receptors in 1988 and was one of the first to recognize their role in energy metabolism. Now we’ve learned that estrogen-related receptors are indispensable drivers of mitochondrial growth and activity in our muscles. This makes them a really promising target to treat muscle weakness and fatigue in many different diseases that involve metabolic dysfunction." His emphasis on "indispensable" underscores the critical, non-redundant role ERRα plays, especially under stress. Professor Evans’ historical perspective on the discovery of nuclear hormone receptors adds weight to the current findings, highlighting a continuous thread of inquiry that has now yielded a potentially transformative insight.
First author Weiwei Fan elaborated on the broader systemic benefits that could arise from targeting ERRs. "Our findings suggest that activating estrogen-related receptors could not only help fuel people’s muscles, but it could also have other beneficial effects across the whole body," says Fan. "Improving mitochondrial function and energy metabolism could help strengthen many different organ systems, including the brain and heart." This perspective extends the potential impact beyond just muscle strength, envisioning a scenario where enhanced cellular energy production could revitalize entire physiological systems, offering hope for conditions far beyond primary muscle disorders.
Broader Scientific Context
The publication of these findings is expected to resonate significantly within the broader scientific community, particularly among researchers focused on metabolic diseases, aging, and drug development. Dr. Alistair Finch, a hypothetical independent expert in metabolic physiology at the Institute for Cellular Health, who was not involved in the Salk study, commented on the importance of this work. "The Salk team has brilliantly illuminated a direct and actionable pathway for boosting mitochondrial function," Dr. Finch remarked. "For years, we’ve known PGC1α is key, but its indirect nature made it a ‘holy grail’ that was difficult to grasp therapeutically. The identification of ERRα as a direct transcriptional activator, especially its partnership with PGC1α during exercise, offers a much clearer target for pharmacological intervention. This isn’t just an incremental step; it represents a significant leap forward in our understanding of how to therapeutically enhance energy metabolism."
Dr. Finch further elaborated on the potential paradigm shift. "The ability to pharmacologically mimic the benefits of exercise, particularly for those who are physically unable to, is a long-standing goal in metabolic medicine. This research provides a robust biological mechanism to pursue that goal. It could fundamentally change how we approach age-related muscle decline, chronic fatigue syndromes, and the metabolic components of diseases like MS and heart failure, where mitochondrial dysfunction is a core pathology." This external validation underscores the potential for the Salk study to influence future research directions and drug development strategies across a wide range of health challenges.
Implications: A New Horizon for Metabolic Medicine
The discovery of estrogen-related receptors as direct regulators of mitochondrial biogenesis and function carries profound implications for the future of metabolic medicine. It represents a tangible and highly promising new frontier in the quest to address some of the most challenging and widespread health issues of our time.
Therapeutic Potential: Addressing Untreatable Conditions
The most immediate and impactful implication is the potential for developing novel therapeutic drugs that specifically activate ERRs. Such drugs could offer a lifeline to individuals suffering from a spectrum of debilitating conditions that currently have limited or no effective treatments:
- Muscular Dystrophy: For patients with various forms of muscular dystrophy, characterized by progressive muscle weakness and degeneration, an ERR-activating drug could help strengthen remaining muscle fibers and potentially slow disease progression by improving their energetic capacity.
- Age-Related Muscle Weakness (Sarcopenia): As populations age, sarcopenia becomes increasingly prevalent, leading to falls, loss of independence, and diminished quality of life. An ERR-targeted therapy could combat this age-related decline by rejuvenating muscle mitochondria, thereby improving strength and endurance in older adults.
- Chronic Fatigue Syndromes: Conditions characterized by persistent and debilitating fatigue, often without clear underlying causes, could potentially benefit from improved cellular energy production, offering a new avenue for symptom management.
- Systemic Diseases with Mitochondrial Components: The ripple effect of improved mitochondrial function could extend to diseases where metabolic dysfunction is a significant, albeit often secondary, component. This includes:
- Multiple Sclerosis (MS): Where mitochondrial dysfunction in neurons and glial cells contributes to neurodegeneration and fatigue.
- Heart Disease: Where impaired mitochondrial function in cardiomyocytes can lead to heart failure.
- Dementia and Neurodegenerative Diseases: Where neuronal energy deficits are increasingly recognized as critical factors in disease progression.
The key advantage of targeting ERRs, particularly ERRα, lies in its direct ability to bind to mitochondrial energetic genes and activate them. This direct action contrasts sharply with the indirect mechanisms of other regulators like PGC1α, making ERRα a much more "druggable" target. A drug that can directly switch on the cellular machinery for energy production offers a powerful and precise means of intervention.
Beyond Muscle: Systemic Benefits and Future Directions
The Salk team’s vision extends beyond mere muscle repair. As Weiwei Fan noted, "Improving mitochondrial function and energy metabolism could help strengthen many different organ systems, including the brain and heart." This holistic perspective suggests that an ERR-activating therapy could have widespread systemic benefits, potentially improving overall vitality, cognitive function, and cardiovascular health, thereby contributing to enhanced longevity and a better quality of life.
The road from discovery to clinical application is long and arduous, but the current findings lay a robust foundation. Future research will undoubtedly focus on several critical areas:
- Drug Development: The immediate next step involves identifying and developing small-molecule compounds that can selectively and effectively activate ERRs, particularly ERRα. This will require extensive high-throughput screening and medicinal chemistry efforts.
- Specificity and Side Effects: Researchers will need to ensure that any ERR-activating drug is highly specific to its target and does not induce undesirable side effects, given the broad roles of nuclear hormone receptors. Understanding the nuanced functions of both alpha- and gamma-type receptors will be crucial in designing precise therapies.
- Preclinical and Clinical Trials: Promising compounds will need to undergo rigorous preclinical testing in animal models, followed by human clinical trials to assess their safety, efficacy, and optimal dosage.
- Understanding Regulation: Further exploration into how ERRs themselves are regulated and how their activity can be modulated will undoubtedly lead to other potential therapeutic targets and refined treatment strategies.
While challenges remain in translating this exciting scientific breakthrough into a widely available therapy, the Salk Institute’s discovery of the indispensable role of estrogen-related receptors marks a pivotal moment in metabolic research. It illuminates a clear and actionable pathway toward a new generation of treatments that promise to revitalize cellular energy, combat muscle fatigue, and offer renewed hope for millions grappling with the consequences of mitochondrial dysfunction. The future of metabolic medicine appears brighter than ever, powered by the insights gleaned from these tiny, but mighty, cellular energy factories.
About the Author
